跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ALPROLIX - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ALPROLIX
Authorized
STANDARD
ALPROLIX
sanofi-aventis canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
85c59ac8e4174504
Company
sanofi-aventis canada inc
Type
Standard
Approval Details
Approval Id
85c59ac8e4174504
Drug Approval Canada Name
ALPROLIX
Product Name
ALPROLIX
Status
Marketed
Status Date
2021-10-22
Original Market Date
2016-01-15
Din
02422956
Drug Class
Human
Dosage Form
Powder For Solution , Kit
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
20:28.16
Atc Original
B02BD04 COAGULATION FACTOR IX
Atc Name
b 02 bd 04
Aig Number
0155510005
Company Name
sanofi-aventis canada inc
Company Address
1755 Steeles Avenue West, Toronto, Ontario, Canada, M2R 3T4
Active Ingredients
RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN
3000 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
85c59ac8e4174504
Type
Standard
Back to Health Canada Approvals